News|Articles|November 17, 2026

FDA clears phase 1/2 trial of androgen receptor antagonist in mCRPC

Author(s)Hannah Clarke
Listen
0:00 / 0:00

Key Takeaways

  • FDA IND clearance enables initiation of ARGATE-001, a first-in-human phase 1/2 study of EIK1006 in metastatic androgen pathway modulation-resistant prostate cancer following anti-hormonal therapy failure.
  • EIK1006 is engineered to inhibit both wild-type AR and clinically relevant AR variants associated with treatment-emergent resistance in advanced disease.
SHOW MORE

The phase 1/2 ARGATE-001 trial will assess the safety, tolerability, and preliminary efficacy of EIK1006 in patients with metastatic androgen pathway modulation-resistant prostate cancer.

EIK1006, an investigational androgen receptor (AR) antagonist designed to target wild-type AR and clinically relevant AR variants, is advancing to clinical evaluation following clearance of its Investigational New Drug (IND) application by the FDA.1 The first-in-human phase 1/2 study will evaluate the agent in patients with advanced metastatic prostate cancer whose disease has progressed following established anti-hormonal therapy.

The planned study, ARGATE-001, will assess the safety, tolerability, and preliminary efficacy of EIK1006 in patients with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), previously metastatic castration-resistant prostate cancer (mCRPC). The investigational agent is intended to address resistance associated with AR pathway alterations, including AR amplification and mutations in the receptor's ligand-binding domain.

Initial dosing is expected to begin in 2027, with preliminary clinical data anticipated in the second half of that year.

“IND clearance for EIK1006 is an important milestone for Eikon and for patients with advanced metastatic prostate cancer, where resistance to current androgen receptor-directed therapies remains a significant challenge. EIK1006’s progression into the clinic reflects the strength of our proprietary drug discovery platform and our ability to nominate novel chemical material and rapidly advance them into human studies,” said Roy Baynes, MD, PhD, Chief Medical Officer of Eikon, in a news release from the company.1 “We look forward to initiating clinical evaluation of EIK1006 and to continuing to translate our platform into potential new medicines for patients with significant unmet need.”

EIK1006's proposed mechanism targets AR-mediated treatment resistance

According to the company, EIK1006 is designed to bind the ligand-binding domain of AR and prevent the receptor from translocating into the nucleus. This is intended to inhibit AR transcriptional activity and downstream signaling. The agent is being developed as a next-generation AR antagonist with activity against both wild-type AR and multiple clinically relevant AR variants that can emerge during treatment with conventional AR-directed therapies.

____

REFERENCE

1. Eikon Therapeutics announces clearance to proceed with first-in-human phase 1/2 study for novel androgen receptor antagonist EIK1006 in advanced metastatic prostate cancer. News release. Eikon Therapeutics. November 17, 2026. Accessed November 17, 2026. https://www.globenewswire.com/news-release/2026/11/17/3404388/0/en/eikon-therapeutics-announces-clearance-to-proceed-with-first-in-human-phase-1-2-study-for-novel-androgen-receptor-antagonist-eik1006-in-advanced-metastatic-prostate-cancer.html


Related to this article